Targeting Signalling Pathways in Hepatocellular Carcinoma

E-ISSN： 1873-4286|23|1|170-175

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.1, 2017-02, pp. : 170-175

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: Hepatocellular carcinoma (HCC) represents the most commonmalignant liver tumor in humans, which incidence and mortality have increased in Europeand United States in the last years. Most patients are diagnosed at an advanced stage, when itis not amenable to curative therapies, so there is an urgent need for new, more effectivetherapeutic tools and strategies. The molecular mechanisms of hepatocarinogenesis andHCC progression have been increasingly understood with intense research in recent years.Methods: The goal of this work is to discuss the different signalling pathways as importantpotential therapeutic targets.Results: Disruption of pathways known to play roles in HCC, such as Wnt/?-catenin,Hedgehog, RAF/MEK/ERK, tryosine kinase receptor-related pathway, Met-HGF, VEGF/VEGF and ROR signalling pathways may be seminal for liver oncogenesis.Conclusion: This review reveals that oncogenes, especially microRNAs that are conserved across species andinterfere with signalling pathways might be used as promising strategies for halting or reversing the progressionof HCC.